Major Depressive Disorder (MDD) Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Product Type
By: HDIN Research
Published: 2025-09-21
Pages: 101
Market Research Report Price
- Single User License (1 Users) $ 3,600
- Team License (2~5 Users) $ 4,600
- Corporate License (>5 Users) $ 5,600
Major Depressive Disorder (MDD) Market Summary
The major depressive disorder (MDD) market revolves around pharmacotherapies that modulate monoamine neurotransmitters and adjunctive pathways to alleviate core symptoms of persistent sadness, anhedonia, and psychomotor changes affecting 280 million globally, with lifetime prevalence nearing 20% in high-income settings. These treatments, from selective serotonin reuptake inhibitors (SSRIs) enhancing synaptic serotonin to atypical antipsychotics (AAPs) balancing dopamine-glutamate via D2/5HT1A agonism, achieve 50-60% response rates in first-line, though 30% require augmentation for treatment-resistant depression. The market's depth stems from multimodal options addressing somatic complaints like insomnia, with innovations in multimodal vortioxetine for cognitive deficits impacting 70% of patients. Real-world remission hovers at 30%, bolstered by biomarkers like BDNF levels guiding personalization, while digital therapeutics integrate for adherence tracking. By 2025, the global MDD market is estimated to be valued between USD 4 billion and USD 7 billion, with a projected compound annual growth rate (CAGR) of 3.5% to 5.5% through 2030. This solid growth reflects surging diagnoses amid post-pandemic mental health crises—up 25% in youth—and APA guidelines favoring rapid-onset esketamine adjuncts, offset by generic saturations eroding 40% of SSRI revenues. The arena navigates stigma reducing help-seeking in 50% of cases, yet leverages telepsychiatry expanding access 3-fold. MDD therapies symbolize psychiatry's biopsychosocial evolution, extending functional years by 5-10 via sustained remission, though polypharmacy risks in 40% comorbidities persist.
Regional Market Trends
The MDD market manifests regional variances, influenced by diagnostic rates, stigma levels, and reimbursement for psychopharmacology.
● North America: Paramount with a CAGR of 3.0%–4.5%, driven by APA screenings and Medicare telehealth. The United States, the apex consumer, propels via Vraylar's adjunctive role in bipolar depression overlaps, urban trends toward vortioxetine for executive dysfunction; Canada's CIHI tracks SSRI uptakes in Indigenous youth.
● Europe: Balanced at a CAGR of 2.5%–4.0%, NICE/EMA pathways harmonize. Germany leads with SHI coverage for brexpiprazole in partial responders, United Kingdom's NHS favoring generics for cost; Nordic registries highlight TCA declines.
● Asia-Pacific: Dynamic CAGR of 4.5%–6.0%, urbanization amplifies. China commands with NMPA approvals for duloxetine amid 54 million cases, Japan's PMDA emphasizes escitalopram for elderly; India's generics flood rural depressions.
● Latin America: Advancing CAGR 3.5%–5.0%, PAHO mental health pacts aid. Brazil tops via SUS sertraline for socioeconomic stressors, urban Rio integrating AAPs.
● Middle East and Africa (MEA): Emerging CAGR 3.0%–4.5%, WHO cascades bridge. Saudi Arabia surges via SFDA vortioxetine for Gulf youth, South Africa's NHIS tackles HIV-depression.
Type Analysis
The MDD market segments by type, each targeting neurotransmitter imbalances with trajectories toward precision and rapid remission.
● Atypical Antipsychotic (AAP): Augmentative CAGR 4.0%–5.5%, cariprazine/Vraylar excels in 30% treatment-resistant via D3 modulation, 25-35% remission uplift per RECOVER; trends probe low-dose for monotherapy, brexpiprazole/Rexulti minimizing akathisia.
● Selective Serotonin Reuptake Inhibitors: Foundational CAGR 3.0%–4.5%, fluoxetine/Prozac legacies 60% first-line with 4-6 week onsets; evolutions include escitalopram/Lexapro for anxiety comorbidity (50%), generics eroding premiums.
● Selective Serotonin Norepinephrine Reuptake Inhibitors: Balanced CAGR 3.5%–5.0%, vortioxetine/Trintellix aids cognition in 40% deficits, duloxetine/Cymbalta dual neuropathic pain; developments spotlight venlafaxine/Effexor biosimilars.
● Tricyclic Antidepressants: Legacy CAGR 2.5%–3.5%, amitriptyline for melancholic subtypes with 50% efficacy but anticholinergic burdens; shifts to adjuncts in chronic pain-depression.
Company Profiles
● Eli Lilly: Cymbalta (duloxetine) sustains SNRI leadership, integrating fibromyalgia overlaps; Lilly's neuroscience pivot eyes ketamine derivatives.
● AbbVie: Vraylar (cariprazine) soared to USD 3–4 billion in 2024, AAP flagship for adjunctive; Celexa (citalopram) and Lexapro (escitalopram) bolster SSRI generics defense.
● Pfizer: Pristiq (desvenlafaxine) carves SNRI niche, legacy from Wyeth; Pfizer's R&D targets inflammation-MDD links.
● Lundbeck: Rexulti/Rxulti (brexpiprazole) generated USD 0.8–0.9 billion in 2024, Otsuka-partnered AAP; Trintellix/Brintellix (vortioxetine) added USD 0.75–0.85 billion, multimodal cognition focus.
● Cheplapharm: Zyprexa (olanzapine) and Seroquel (quetiapine) sustain AAP via acquisitions, European-centric.
● Viatris: Generic Zoloft (sertraline) USD 0.2–0.3 billion 2024, Effexor (venlafaxine) same; generics scale aids affordability.
● Apotex: Paxil (paroxetine) generics for Canadian exports.
● OTSUKA: Abilify (aripiprazole) AAP staple, Lundbeck synergies.
● Sandoz: SSRI biosimilars for EU tenders.
● Teva: Generic amitriptyline for TCA niches.
● Dr. Reddy's: SNRI generics for APAC.
● Sun Pharma: Escitalopram exports.
● Glenmark: Vortioxetine analogs.
● LUPIN: Fluoxetine for African tenders.
Industry Value Chain Analysis
The MDD value chain fuses neuropharmacology with psychosocial integrations, from serotonin assays to remission tracking. Upstream R&D deploys PET imaging for 5HT1A occupancy, AI-phenotyping for subtypes; Phase III per HAM-D scales cost USD 500 million, FDA's BTD expediting. Clinicals harness STAR*D designs, biomarkers like CRP for inflammation, EMA's PRIME for orphans. Midstream synthesizes vortioxetine's azapindole via Suzuki couplings, HPLC to 99.8%; Indian CMOs scale 100 tons. Formulation enteric-coats TCAs, blister-packed. Downstream logistics to pharmacies, Lilly's apps for adherence. Marketing via APA congresses, HEOR $50K/QALY. Support telepsych and suicide hotlines, FAERS for SSRI risks. Verticals like AbbVie streamline from trials to RWE.
Opportunities and Challenges
Opportunities:
● Biomarker Personalization: BDNF-guided dosing uplifts 30% responses, $2B TRD TAM.
● Digital Adjuncts: Apps boost adherence 40%, youth markets.
● Emerging Burdens: APAC's 25% rise via screenings.
● AAP Expansions: Low-dose monotherapy for 20% non-remitters.
Challenges:
● Resistance Heterogeneity: 30% TRD demands sequencing, inflating trials.
● Stigma Barriers: 50% undertreatment in MEA.
● Generic Cliffs: SSRI erosions void $1B, R&D squeeze.
● Side Effect Burdens: AAP metabolic risks in 20%.
The major depressive disorder (MDD) market revolves around pharmacotherapies that modulate monoamine neurotransmitters and adjunctive pathways to alleviate core symptoms of persistent sadness, anhedonia, and psychomotor changes affecting 280 million globally, with lifetime prevalence nearing 20% in high-income settings. These treatments, from selective serotonin reuptake inhibitors (SSRIs) enhancing synaptic serotonin to atypical antipsychotics (AAPs) balancing dopamine-glutamate via D2/5HT1A agonism, achieve 50-60% response rates in first-line, though 30% require augmentation for treatment-resistant depression. The market's depth stems from multimodal options addressing somatic complaints like insomnia, with innovations in multimodal vortioxetine for cognitive deficits impacting 70% of patients. Real-world remission hovers at 30%, bolstered by biomarkers like BDNF levels guiding personalization, while digital therapeutics integrate for adherence tracking. By 2025, the global MDD market is estimated to be valued between USD 4 billion and USD 7 billion, with a projected compound annual growth rate (CAGR) of 3.5% to 5.5% through 2030. This solid growth reflects surging diagnoses amid post-pandemic mental health crises—up 25% in youth—and APA guidelines favoring rapid-onset esketamine adjuncts, offset by generic saturations eroding 40% of SSRI revenues. The arena navigates stigma reducing help-seeking in 50% of cases, yet leverages telepsychiatry expanding access 3-fold. MDD therapies symbolize psychiatry's biopsychosocial evolution, extending functional years by 5-10 via sustained remission, though polypharmacy risks in 40% comorbidities persist.
Regional Market Trends
The MDD market manifests regional variances, influenced by diagnostic rates, stigma levels, and reimbursement for psychopharmacology.
● North America: Paramount with a CAGR of 3.0%–4.5%, driven by APA screenings and Medicare telehealth. The United States, the apex consumer, propels via Vraylar's adjunctive role in bipolar depression overlaps, urban trends toward vortioxetine for executive dysfunction; Canada's CIHI tracks SSRI uptakes in Indigenous youth.
● Europe: Balanced at a CAGR of 2.5%–4.0%, NICE/EMA pathways harmonize. Germany leads with SHI coverage for brexpiprazole in partial responders, United Kingdom's NHS favoring generics for cost; Nordic registries highlight TCA declines.
● Asia-Pacific: Dynamic CAGR of 4.5%–6.0%, urbanization amplifies. China commands with NMPA approvals for duloxetine amid 54 million cases, Japan's PMDA emphasizes escitalopram for elderly; India's generics flood rural depressions.
● Latin America: Advancing CAGR 3.5%–5.0%, PAHO mental health pacts aid. Brazil tops via SUS sertraline for socioeconomic stressors, urban Rio integrating AAPs.
● Middle East and Africa (MEA): Emerging CAGR 3.0%–4.5%, WHO cascades bridge. Saudi Arabia surges via SFDA vortioxetine for Gulf youth, South Africa's NHIS tackles HIV-depression.
Type Analysis
The MDD market segments by type, each targeting neurotransmitter imbalances with trajectories toward precision and rapid remission.
● Atypical Antipsychotic (AAP): Augmentative CAGR 4.0%–5.5%, cariprazine/Vraylar excels in 30% treatment-resistant via D3 modulation, 25-35% remission uplift per RECOVER; trends probe low-dose for monotherapy, brexpiprazole/Rexulti minimizing akathisia.
● Selective Serotonin Reuptake Inhibitors: Foundational CAGR 3.0%–4.5%, fluoxetine/Prozac legacies 60% first-line with 4-6 week onsets; evolutions include escitalopram/Lexapro for anxiety comorbidity (50%), generics eroding premiums.
● Selective Serotonin Norepinephrine Reuptake Inhibitors: Balanced CAGR 3.5%–5.0%, vortioxetine/Trintellix aids cognition in 40% deficits, duloxetine/Cymbalta dual neuropathic pain; developments spotlight venlafaxine/Effexor biosimilars.
● Tricyclic Antidepressants: Legacy CAGR 2.5%–3.5%, amitriptyline for melancholic subtypes with 50% efficacy but anticholinergic burdens; shifts to adjuncts in chronic pain-depression.
Company Profiles
● Eli Lilly: Cymbalta (duloxetine) sustains SNRI leadership, integrating fibromyalgia overlaps; Lilly's neuroscience pivot eyes ketamine derivatives.
● AbbVie: Vraylar (cariprazine) soared to USD 3–4 billion in 2024, AAP flagship for adjunctive; Celexa (citalopram) and Lexapro (escitalopram) bolster SSRI generics defense.
● Pfizer: Pristiq (desvenlafaxine) carves SNRI niche, legacy from Wyeth; Pfizer's R&D targets inflammation-MDD links.
● Lundbeck: Rexulti/Rxulti (brexpiprazole) generated USD 0.8–0.9 billion in 2024, Otsuka-partnered AAP; Trintellix/Brintellix (vortioxetine) added USD 0.75–0.85 billion, multimodal cognition focus.
● Cheplapharm: Zyprexa (olanzapine) and Seroquel (quetiapine) sustain AAP via acquisitions, European-centric.
● Viatris: Generic Zoloft (sertraline) USD 0.2–0.3 billion 2024, Effexor (venlafaxine) same; generics scale aids affordability.
● Apotex: Paxil (paroxetine) generics for Canadian exports.
● OTSUKA: Abilify (aripiprazole) AAP staple, Lundbeck synergies.
● Sandoz: SSRI biosimilars for EU tenders.
● Teva: Generic amitriptyline for TCA niches.
● Dr. Reddy's: SNRI generics for APAC.
● Sun Pharma: Escitalopram exports.
● Glenmark: Vortioxetine analogs.
● LUPIN: Fluoxetine for African tenders.
Industry Value Chain Analysis
The MDD value chain fuses neuropharmacology with psychosocial integrations, from serotonin assays to remission tracking. Upstream R&D deploys PET imaging for 5HT1A occupancy, AI-phenotyping for subtypes; Phase III per HAM-D scales cost USD 500 million, FDA's BTD expediting. Clinicals harness STAR*D designs, biomarkers like CRP for inflammation, EMA's PRIME for orphans. Midstream synthesizes vortioxetine's azapindole via Suzuki couplings, HPLC to 99.8%; Indian CMOs scale 100 tons. Formulation enteric-coats TCAs, blister-packed. Downstream logistics to pharmacies, Lilly's apps for adherence. Marketing via APA congresses, HEOR $50K/QALY. Support telepsych and suicide hotlines, FAERS for SSRI risks. Verticals like AbbVie streamline from trials to RWE.
Opportunities and Challenges
Opportunities:
● Biomarker Personalization: BDNF-guided dosing uplifts 30% responses, $2B TRD TAM.
● Digital Adjuncts: Apps boost adherence 40%, youth markets.
● Emerging Burdens: APAC's 25% rise via screenings.
● AAP Expansions: Low-dose monotherapy for 20% non-remitters.
Challenges:
● Resistance Heterogeneity: 30% TRD demands sequencing, inflating trials.
● Stigma Barriers: 50% undertreatment in MEA.
● Generic Cliffs: SSRI erosions void $1B, R&D squeeze.
● Side Effect Burdens: AAP metabolic risks in 20%.
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Major Depressive Disorder (MDD) Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Major Depressive Disorder (MDD) Market in North America (2020-2030)
8.1 Major Depressive Disorder (MDD) Market Size
8.2 Major Depressive Disorder (MDD) Market by End Use
8.3 Competition by Players/Suppliers
8.4 Major Depressive Disorder (MDD) Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Major Depressive Disorder (MDD) Market in South America (2020-2030)
9.1 Major Depressive Disorder (MDD) Market Size
9.2 Major Depressive Disorder (MDD) Market by End Use
9.3 Competition by Players/Suppliers
9.4 Major Depressive Disorder (MDD) Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Major Depressive Disorder (MDD) Market in Asia & Pacific (2020-2030)
10.1 Major Depressive Disorder (MDD) Market Size
10.2 Major Depressive Disorder (MDD) Market by End Use
10.3 Competition by Players/Suppliers
10.4 Major Depressive Disorder (MDD) Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southest Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Major Depressive Disorder (MDD) Market in Europe (2020-2030)
11.1 Major Depressive Disorder (MDD) Market Size
11.2 Major Depressive Disorder (MDD) Market by End Use
11.3 Competition by Players/Suppliers
11.4 Major Depressive Disorder (MDD) Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Major Depressive Disorder (MDD) Market in MEA (2020-2030)
12.1 Major Depressive Disorder (MDD) Market Size
12.2 Major Depressive Disorder (MDD) Market by End Use
12.3 Competition by Players/Suppliers
12.4 Major Depressive Disorder (MDD) Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Major Depressive Disorder (MDD) Market (2020-2025)
13.1 Major Depressive Disorder (MDD) Market Size
13.2 Major Depressive Disorder (MDD) Market by End Use
13.3 Competition by Players/Suppliers
13.4 Major Depressive Disorder (MDD) Market Size by Type
Chapter 14 Global Major Depressive Disorder (MDD) Market Forecast (2025-2030)
14.1 Major Depressive Disorder (MDD) Market Size Forecast
14.2 Major Depressive Disorder (MDD) Application Forecast
14.3 Competition by Players/Suppliers
14.4 Major Depressive Disorder (MDD) Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 Eli Lilly
15.1.1 Company Profile
15.1.2 Main Business and Major Depressive Disorder (MDD) Information
15.1.3 SWOT Analysis of Eli Lilly
15.1.4 Eli Lilly Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.2 AbbVie
15.2.1 Company Profile
15.2.2 Main Business and Major Depressive Disorder (MDD) Information
15.2.3 SWOT Analysis of AbbVie
15.2.4 AbbVie Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.3 Pfizer
15.3.1 Company Profile
15.3.2 Main Business and Major Depressive Disorder (MDD) Information
15.3.3 SWOT Analysis of Pfizer
15.3.4 Pfizer Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.4 Lundbeck
15.4.1 Company Profile
15.4.2 Main Business and Major Depressive Disorder (MDD) Information
15.4.3 SWOT Analysis of Lundbeck
15.4.4 Lundbeck Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.5 Cheplapharm
15.5.1 Company Profile
15.5.2 Main Business and Major Depressive Disorder (MDD) Information
15.5.3 SWOT Analysis of Cheplapharm
15.5.4 Cheplapharm Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.6 Viatris
15.6.1 Company Profile
15.6.2 Main Business and Major Depressive Disorder (MDD) Information
15.6.3 SWOT Analysis of Viatris
15.6.4 Viatris Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.7 Apotex
15.7.1 Company Profile
15.7.2 Main Business and Major Depressive Disorder (MDD) Information
15.7.3 SWOT Analysis of Apotex
15.7.4 Apotex Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.8 OTSUKA
15.8.1 Company Profile
15.8.2 Main Business and Major Depressive Disorder (MDD) Information
15.8.3 SWOT Analysis of OTSUKA
15.8.4 OTSUKA Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.9 Sandoz
15.9.1 Company Profile
15.9.2 Main Business and Major Depressive Disorder (MDD) Information
15.9.3 SWOT Analysis of Sandoz
15.9.4 Sandoz Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.10 Teva Pharmaceuticals
15.10.1 Company Profile
15.10.2 Main Business and Major Depressive Disorder (MDD) Information
15.10.3 SWOT Analysis of Teva Pharmaceuticals
15.10.4 Teva Pharmaceuticals Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.11 Dr. Reddy's Laboratories
15.11.1 Company Profile
15.11.2 Main Business and Major Depressive Disorder (MDD) Information
15.11.3 SWOT Analysis of Dr. Reddy's Laboratories
15.11.4 Dr. Reddy's Laboratories Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.12 Sun Pharma
15.12.1 Company Profile
15.12.2 Main Business and Major Depressive Disorder (MDD) Information
15.12.3 SWOT Analysis of Sun Pharma
15.12.4 Sun Pharma Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.13 Glenmark Pharma
15.13.1 Company Profile
15.13.2 Main Business and Major Depressive Disorder (MDD) Information
15.13.3 SWOT Analysis of Glenmark Pharma
15.13.4 Glenmark Pharma Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
Please ask for sample pages for full companies list
Chapter 1 Executive Summary
Chapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Major Depressive Disorder (MDD) Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Major Depressive Disorder (MDD) Market in North America (2020-2030)
8.1 Major Depressive Disorder (MDD) Market Size
8.2 Major Depressive Disorder (MDD) Market by End Use
8.3 Competition by Players/Suppliers
8.4 Major Depressive Disorder (MDD) Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Major Depressive Disorder (MDD) Market in South America (2020-2030)
9.1 Major Depressive Disorder (MDD) Market Size
9.2 Major Depressive Disorder (MDD) Market by End Use
9.3 Competition by Players/Suppliers
9.4 Major Depressive Disorder (MDD) Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Major Depressive Disorder (MDD) Market in Asia & Pacific (2020-2030)
10.1 Major Depressive Disorder (MDD) Market Size
10.2 Major Depressive Disorder (MDD) Market by End Use
10.3 Competition by Players/Suppliers
10.4 Major Depressive Disorder (MDD) Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southest Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Major Depressive Disorder (MDD) Market in Europe (2020-2030)
11.1 Major Depressive Disorder (MDD) Market Size
11.2 Major Depressive Disorder (MDD) Market by End Use
11.3 Competition by Players/Suppliers
11.4 Major Depressive Disorder (MDD) Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Major Depressive Disorder (MDD) Market in MEA (2020-2030)
12.1 Major Depressive Disorder (MDD) Market Size
12.2 Major Depressive Disorder (MDD) Market by End Use
12.3 Competition by Players/Suppliers
12.4 Major Depressive Disorder (MDD) Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Major Depressive Disorder (MDD) Market (2020-2025)
13.1 Major Depressive Disorder (MDD) Market Size
13.2 Major Depressive Disorder (MDD) Market by End Use
13.3 Competition by Players/Suppliers
13.4 Major Depressive Disorder (MDD) Market Size by Type
Chapter 14 Global Major Depressive Disorder (MDD) Market Forecast (2025-2030)
14.1 Major Depressive Disorder (MDD) Market Size Forecast
14.2 Major Depressive Disorder (MDD) Application Forecast
14.3 Competition by Players/Suppliers
14.4 Major Depressive Disorder (MDD) Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 Eli Lilly
15.1.1 Company Profile
15.1.2 Main Business and Major Depressive Disorder (MDD) Information
15.1.3 SWOT Analysis of Eli Lilly
15.1.4 Eli Lilly Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.2 AbbVie
15.2.1 Company Profile
15.2.2 Main Business and Major Depressive Disorder (MDD) Information
15.2.3 SWOT Analysis of AbbVie
15.2.4 AbbVie Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.3 Pfizer
15.3.1 Company Profile
15.3.2 Main Business and Major Depressive Disorder (MDD) Information
15.3.3 SWOT Analysis of Pfizer
15.3.4 Pfizer Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.4 Lundbeck
15.4.1 Company Profile
15.4.2 Main Business and Major Depressive Disorder (MDD) Information
15.4.3 SWOT Analysis of Lundbeck
15.4.4 Lundbeck Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.5 Cheplapharm
15.5.1 Company Profile
15.5.2 Main Business and Major Depressive Disorder (MDD) Information
15.5.3 SWOT Analysis of Cheplapharm
15.5.4 Cheplapharm Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.6 Viatris
15.6.1 Company Profile
15.6.2 Main Business and Major Depressive Disorder (MDD) Information
15.6.3 SWOT Analysis of Viatris
15.6.4 Viatris Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.7 Apotex
15.7.1 Company Profile
15.7.2 Main Business and Major Depressive Disorder (MDD) Information
15.7.3 SWOT Analysis of Apotex
15.7.4 Apotex Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.8 OTSUKA
15.8.1 Company Profile
15.8.2 Main Business and Major Depressive Disorder (MDD) Information
15.8.3 SWOT Analysis of OTSUKA
15.8.4 OTSUKA Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.9 Sandoz
15.9.1 Company Profile
15.9.2 Main Business and Major Depressive Disorder (MDD) Information
15.9.3 SWOT Analysis of Sandoz
15.9.4 Sandoz Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.10 Teva Pharmaceuticals
15.10.1 Company Profile
15.10.2 Main Business and Major Depressive Disorder (MDD) Information
15.10.3 SWOT Analysis of Teva Pharmaceuticals
15.10.4 Teva Pharmaceuticals Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.11 Dr. Reddy's Laboratories
15.11.1 Company Profile
15.11.2 Main Business and Major Depressive Disorder (MDD) Information
15.11.3 SWOT Analysis of Dr. Reddy's Laboratories
15.11.4 Dr. Reddy's Laboratories Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.12 Sun Pharma
15.12.1 Company Profile
15.12.2 Main Business and Major Depressive Disorder (MDD) Information
15.12.3 SWOT Analysis of Sun Pharma
15.12.4 Sun Pharma Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
15.13 Glenmark Pharma
15.13.1 Company Profile
15.13.2 Main Business and Major Depressive Disorder (MDD) Information
15.13.3 SWOT Analysis of Glenmark Pharma
15.13.4 Glenmark Pharma Major Depressive Disorder (MDD) Sales, Revenue, Price and Gross Margin (2020-2025)
Please ask for sample pages for full companies list
Table Abbreviation and Acronyms
Table Research Scope of Major Depressive Disorder (MDD) Report
Table Data Sources of Major Depressive Disorder (MDD) Report
Table Major Assumptions of Major Depressive Disorder (MDD) Report
Table Major Depressive Disorder (MDD) Classification
Table Major Depressive Disorder (MDD) Applications
Table Drivers of Major Depressive Disorder (MDD) Market
Table Restraints of Major Depressive Disorder (MDD) Market
Table Opportunities of Major Depressive Disorder (MDD) Market
Table Threats of Major Depressive Disorder (MDD) Market
Table Raw Materials Suppliers
Table Different Production Methods of Major Depressive Disorder (MDD)
Table Cost Structure Analysis of Major Depressive Disorder (MDD)
Table Key End Users
Table Latest News of Major Depressive Disorder (MDD) Market
Table Merger and Acquisition
Table Planned/Future Project of Major Depressive Disorder (MDD) Market
Table Policy of Major Depressive Disorder (MDD) Market
Table 2020-2030 North America Major Depressive Disorder (MDD) Market Size
Table 2020-2030 North America Major Depressive Disorder (MDD) Market Size by Application
Table 2020-2025 North America Major Depressive Disorder (MDD) Key Players Revenue
Table 2020-2025 North America Major Depressive Disorder (MDD) Key Players Market Share
Table 2020-2030 North America Major Depressive Disorder (MDD) Market Size by Type
Table 2020-2030 United States Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Canada Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Mexico Major Depressive Disorder (MDD) Market Size
Table 2020-2030 South America Major Depressive Disorder (MDD) Market Size
Table 2020-2030 South America Major Depressive Disorder (MDD) Market Size by Application
Table 2020-2025 South America Major Depressive Disorder (MDD) Key Players Revenue
Table 2020-2025 South America Major Depressive Disorder (MDD) Key Players Market Share
Table 2020-2030 South America Major Depressive Disorder (MDD) Market Size by Type
Table 2020-2030 Brazil Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Argentina Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Chile Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Peru Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Asia & Pacific Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Asia & Pacific Major Depressive Disorder (MDD) Market Size by Application
Table 2020-2025 Asia & Pacific Major Depressive Disorder (MDD) Key Players Revenue
Table 2020-2025 Asia & Pacific Major Depressive Disorder (MDD) Key Players Market Share
Table 2020-2030 Asia & Pacific Major Depressive Disorder (MDD) Market Size by Type
Table 2020-2030 China Major Depressive Disorder (MDD) Market Size
Table 2020-2030 India Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Japan Major Depressive Disorder (MDD) Market Size
Table 2020-2030 South Korea Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Southeast Asia Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Australia Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Europe Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Europe Major Depressive Disorder (MDD) Market Size by Application
Table 2020-2025 Europe Major Depressive Disorder (MDD) Key Players Revenue
Table 2020-2025 Europe Major Depressive Disorder (MDD) Key Players Market Share
Table 2020-2030 Europe Major Depressive Disorder (MDD) Market Size by Type
Table 2020-2030 Germany Major Depressive Disorder (MDD) Market Size
Table 2020-2030 France Major Depressive Disorder (MDD) Market Size
Table 2020-2030 United Kingdom Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Italy Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Spain Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Belgium Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Netherlands Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Austria Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Poland Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Russia Major Depressive Disorder (MDD) Market Size
Table 2020-2030 MEA Major Depressive Disorder (MDD) Market Size
Table 2020-2030 MEA Major Depressive Disorder (MDD) Market Size by Application
Table 2020-2025 MEA Major Depressive Disorder (MDD) Key Players Revenue
Table 2020-2025 MEA Major Depressive Disorder (MDD) Key Players Market Share
Table 2020-2030 MEA Major Depressive Disorder (MDD) Market Size by Type
Table 2020-2030 Egypt Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Israel Major Depressive Disorder (MDD) Market Size
Table 2020-2030 South Africa Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Gulf Cooperation Council Countries Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Turkey Major Depressive Disorder (MDD) Market Size
Table 2020-2025 Global Major Depressive Disorder (MDD) Market Size by Region
Table 2020-2025 Global Major Depressive Disorder (MDD) Market Size Share by Region
Table 2020-2025 Global Major Depressive Disorder (MDD) Market Size by Application
Table 2020-2025 Global Major Depressive Disorder (MDD) Market Share by Application
Table 2020-2025 Global Major Depressive Disorder (MDD) Key Vendors Revenue
Table 2020-2025 Global Major Depressive Disorder (MDD) Key Vendors Market Share
Table 2020-2025 Global Major Depressive Disorder (MDD) Market Size by Type
Table 2020-2025 Global Major Depressive Disorder (MDD) Market Share by Type
Table 2025-2030 Global Major Depressive Disorder (MDD) Market Size by Region
Table 2025-2030 Global Major Depressive Disorder (MDD) Market Size Share by Region
Table 2025-2030 Global Major Depressive Disorder (MDD) Market Size by Application
Table 2025-2030 Global Major Depressive Disorder (MDD) Market Share by Application
Table 2025-2030 Global Major Depressive Disorder (MDD) Key Vendors Revenue
Table 2025-2030 Global Major Depressive Disorder (MDD) Key Vendors Market Share
Table 2025-2030 Global Major Depressive Disorder (MDD) Market Size by Type
Table 2025-2030 Major Depressive Disorder (MDD) Global Market Share by Type
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Major Depressive Disorder (MDD) Picture
Figure 2020-2030 North America Major Depressive Disorder (MDD) Market Size and CAGR
Figure 2020-2030 South America Major Depressive Disorder (MDD) Market Size and CAGR
Figure 2020-2030 Asia & Pacific Major Depressive Disorder (MDD) Market Size and CAGR
Figure 2020-2030 Europe Major Depressive Disorder (MDD) Market Size and CAGR
Figure 2020-2030 MEA Major Depressive Disorder (MDD) Market Size and CAGR
Figure 2020-2025 Global Major Depressive Disorder (MDD) Market Size and Growth Rate
Figure 2025-2030 Global Major Depressive Disorder (MDD) Market Size and Growth Rate
Table Research Scope of Major Depressive Disorder (MDD) Report
Table Data Sources of Major Depressive Disorder (MDD) Report
Table Major Assumptions of Major Depressive Disorder (MDD) Report
Table Major Depressive Disorder (MDD) Classification
Table Major Depressive Disorder (MDD) Applications
Table Drivers of Major Depressive Disorder (MDD) Market
Table Restraints of Major Depressive Disorder (MDD) Market
Table Opportunities of Major Depressive Disorder (MDD) Market
Table Threats of Major Depressive Disorder (MDD) Market
Table Raw Materials Suppliers
Table Different Production Methods of Major Depressive Disorder (MDD)
Table Cost Structure Analysis of Major Depressive Disorder (MDD)
Table Key End Users
Table Latest News of Major Depressive Disorder (MDD) Market
Table Merger and Acquisition
Table Planned/Future Project of Major Depressive Disorder (MDD) Market
Table Policy of Major Depressive Disorder (MDD) Market
Table 2020-2030 North America Major Depressive Disorder (MDD) Market Size
Table 2020-2030 North America Major Depressive Disorder (MDD) Market Size by Application
Table 2020-2025 North America Major Depressive Disorder (MDD) Key Players Revenue
Table 2020-2025 North America Major Depressive Disorder (MDD) Key Players Market Share
Table 2020-2030 North America Major Depressive Disorder (MDD) Market Size by Type
Table 2020-2030 United States Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Canada Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Mexico Major Depressive Disorder (MDD) Market Size
Table 2020-2030 South America Major Depressive Disorder (MDD) Market Size
Table 2020-2030 South America Major Depressive Disorder (MDD) Market Size by Application
Table 2020-2025 South America Major Depressive Disorder (MDD) Key Players Revenue
Table 2020-2025 South America Major Depressive Disorder (MDD) Key Players Market Share
Table 2020-2030 South America Major Depressive Disorder (MDD) Market Size by Type
Table 2020-2030 Brazil Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Argentina Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Chile Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Peru Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Asia & Pacific Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Asia & Pacific Major Depressive Disorder (MDD) Market Size by Application
Table 2020-2025 Asia & Pacific Major Depressive Disorder (MDD) Key Players Revenue
Table 2020-2025 Asia & Pacific Major Depressive Disorder (MDD) Key Players Market Share
Table 2020-2030 Asia & Pacific Major Depressive Disorder (MDD) Market Size by Type
Table 2020-2030 China Major Depressive Disorder (MDD) Market Size
Table 2020-2030 India Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Japan Major Depressive Disorder (MDD) Market Size
Table 2020-2030 South Korea Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Southeast Asia Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Australia Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Europe Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Europe Major Depressive Disorder (MDD) Market Size by Application
Table 2020-2025 Europe Major Depressive Disorder (MDD) Key Players Revenue
Table 2020-2025 Europe Major Depressive Disorder (MDD) Key Players Market Share
Table 2020-2030 Europe Major Depressive Disorder (MDD) Market Size by Type
Table 2020-2030 Germany Major Depressive Disorder (MDD) Market Size
Table 2020-2030 France Major Depressive Disorder (MDD) Market Size
Table 2020-2030 United Kingdom Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Italy Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Spain Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Belgium Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Netherlands Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Austria Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Poland Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Russia Major Depressive Disorder (MDD) Market Size
Table 2020-2030 MEA Major Depressive Disorder (MDD) Market Size
Table 2020-2030 MEA Major Depressive Disorder (MDD) Market Size by Application
Table 2020-2025 MEA Major Depressive Disorder (MDD) Key Players Revenue
Table 2020-2025 MEA Major Depressive Disorder (MDD) Key Players Market Share
Table 2020-2030 MEA Major Depressive Disorder (MDD) Market Size by Type
Table 2020-2030 Egypt Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Israel Major Depressive Disorder (MDD) Market Size
Table 2020-2030 South Africa Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Gulf Cooperation Council Countries Major Depressive Disorder (MDD) Market Size
Table 2020-2030 Turkey Major Depressive Disorder (MDD) Market Size
Table 2020-2025 Global Major Depressive Disorder (MDD) Market Size by Region
Table 2020-2025 Global Major Depressive Disorder (MDD) Market Size Share by Region
Table 2020-2025 Global Major Depressive Disorder (MDD) Market Size by Application
Table 2020-2025 Global Major Depressive Disorder (MDD) Market Share by Application
Table 2020-2025 Global Major Depressive Disorder (MDD) Key Vendors Revenue
Table 2020-2025 Global Major Depressive Disorder (MDD) Key Vendors Market Share
Table 2020-2025 Global Major Depressive Disorder (MDD) Market Size by Type
Table 2020-2025 Global Major Depressive Disorder (MDD) Market Share by Type
Table 2025-2030 Global Major Depressive Disorder (MDD) Market Size by Region
Table 2025-2030 Global Major Depressive Disorder (MDD) Market Size Share by Region
Table 2025-2030 Global Major Depressive Disorder (MDD) Market Size by Application
Table 2025-2030 Global Major Depressive Disorder (MDD) Market Share by Application
Table 2025-2030 Global Major Depressive Disorder (MDD) Key Vendors Revenue
Table 2025-2030 Global Major Depressive Disorder (MDD) Key Vendors Market Share
Table 2025-2030 Global Major Depressive Disorder (MDD) Market Size by Type
Table 2025-2030 Major Depressive Disorder (MDD) Global Market Share by Type
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Major Depressive Disorder (MDD) Picture
Figure 2020-2030 North America Major Depressive Disorder (MDD) Market Size and CAGR
Figure 2020-2030 South America Major Depressive Disorder (MDD) Market Size and CAGR
Figure 2020-2030 Asia & Pacific Major Depressive Disorder (MDD) Market Size and CAGR
Figure 2020-2030 Europe Major Depressive Disorder (MDD) Market Size and CAGR
Figure 2020-2030 MEA Major Depressive Disorder (MDD) Market Size and CAGR
Figure 2020-2025 Global Major Depressive Disorder (MDD) Market Size and Growth Rate
Figure 2025-2030 Global Major Depressive Disorder (MDD) Market Size and Growth Rate
Research Methodology
- Market Estimated Methodology:
Bottom-up & top-down approach, supply & demand approach are the most important method which is used by HDIN Research to estimate the market size.
1）Top-down & Bottom-up Approach
Top-down approach uses a general market size figure and determines the percentage that the objective market represents.
Bottom-up approach size the objective market by collecting the sub-segment information.
2）Supply & Demand Approach
Supply approach is based on assessments of the size of each competitor supplying the objective market.
Demand approach combine end-user data within a market to estimate the objective market size. It is sometimes referred to as bottom-up approach.
- Forecasting Methodology
- Numerous factors impacting the market trend are considered for forecast model:
- New technology and application in the future;
- New project planned/under contraction;
- Global and regional underlying economic growth;
- Threatens of substitute products;
- Industry expert opinion;
- Policy and Society implication.
- Analysis Tools
1）PEST Analysis
PEST Analysis is a simple and widely used tool that helps our client analyze the Political, Economic, Socio-Cultural, and Technological changes in their business environment.
- Benefits of a PEST analysis:
- It helps you to spot business opportunities, and it gives you advanced warning of significant threats.
- It reveals the direction of change within your business environment. This helps you shape what you’re doing, so that you work with change, rather than against it.
- It helps you avoid starting projects that are likely to fail, for reasons beyond your control.
- It can help you break free of unconscious assumptions when you enter a new country, region, or market; because it helps you develop an objective view of this new environment.
2）Porter’s Five Force Model Analysis
The Porter’s Five Force Model is a tool that can be used to analyze the opportunities and overall competitive advantage. The five forces that can assist in determining the competitive intensity and potential attractiveness within a specific area.
- Threat of New Entrants: Profitable industries that yield high returns will attract new firms.
- Threat of Substitutes: A substitute product uses a different technology to try to solve the same economic need.
- Bargaining Power of Customers: the ability of customers to put the firm under pressure, which also affects the customer's sensitivity to price changes.
- Bargaining Power of Suppliers: Suppliers of raw materials, components, labor, and services (such as expertise) to the firm can be a source of power over the firm when there are few substitutes.
- Competitive Rivalry: For most industries the intensity of competitive rivalry is the major determinant of the competitiveness of the industry.
3）Value Chain Analysis
Value chain analysis is a tool to identify activities, within and around the firm and relating these activities to an assessment of competitive strength. Value chain can be analyzed by primary activities and supportive activities. Primary activities include: inbound logistics, operations, outbound logistics, marketing & sales, service. Support activities include: technology development, human resource management, management, finance, legal, planning.
4）SWOT Analysis
SWOT analysis is a tool used to evaluate a company's competitive position by identifying its strengths, weaknesses, opportunities and threats. The strengths and weakness is the inner factor; the opportunities and threats are the external factor. By analyzing the inner and external factors, the analysis can provide the detail information of the position of a player and the characteristics of the industry.
- Strengths describe what the player excels at and separates it from the competition
- Weaknesses stop the player from performing at its optimum level.
- Opportunities refer to favorable external factors that the player can use to give it a competitive advantage.
- Threats refer to factors that have the potential to harm the player.
- Data Sources
| Primary Sources | Secondary Sources |
|---|---|
| Face to face/Phone Interviews with market participants, such as: Manufactures; Distributors; End-users; Experts. Online Survey |
Government/International Organization Data: Annual Report/Presentation/Fact Book Internet Source Information Industry Association Data Free/Purchased Database Market Research Report Book/Journal/News |